

Fig. 6: Secreted metabolites from skin isolates inhibits fungal growth. a, Kirby-Bauer dics diffusion susceptibility test to examine the sensitivity of C. auris B11211 and C. albicans K1 in crude extracts (40 mg/mL) and active fractions from Micrococcus luteus LK1117 (first row), Microbacterium sp. LK369 (second row), and Helcobacillus massiliensis LK130 (third row). Zones of inhibition were measured after 24h incubation at 37°C. **b**, Schematic of neotropenic mouse model of Candidiasis. CFU measurements were taken 48h post-infection. Mice were rendered neutropenic using cyclophosphamide (150 mg/kg at day -4, 100 mg/kg at day -1, and 100 mg/kg at day +2). Animals were infected via lateral tail vein with 0.1 mL inoculum (CFU/mL) 2h prior to treatment. mmunocompromised mice received 200μL (high dose) and 100μL (low dose) of active fraction (10mg/kg) via intraperitoneal injection. **c**, Log reduction (CFU/thigh) of C. albicans in active fractions.